Year in Review: Updates in Treating Myelofibrosis - Episode 8

Key Efficacy and Safety Takeaways From Recent Data on JAK Inhibitors for MF

,

Drs Rampal and Kuykendall highlight the benefits of pacritinib for patients with low platelet counts, as evidenced by the PERSIST-2 study, and momelotinib for patients with anemia, as shown in the MOMENTUM Phase 3 Study, focusing on their efficacy in spleen volume reduction and symptom relief in patients with myelofibrosis.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: How JAK Inhibitors Have Shaped the Landscape of MF
    EP. 2: Pelabresib Plus Ruxolitinib for JAK Inhibitor-Naïve Patients: Data From MANIFEST and MANIFEST-2
    EP. 3: Navitoclax Plus Ruxolitinib for Untreated MF: Data From TRANSFORM-1
    EP. 4: Navtemadlin Plus Ruxolitinib for Patients With MF who had Suboptimal Responses to Ruxolitinib
    EP. 5: Selinexor Plus Ruxolitinib in JAK Inhibitor-Naïve Patients: Updated Results From XPORT-MF-034
    EP. 6: Luspatercept With or Without Ruxolitinib for the Treatment of Anemia in Patients With MF: Data From ACE-536-MF-001
    EP. 7: Future Directions in Combination Therapies for Myelofibrosis
    Now Viewing
    EP. 8: Key Efficacy and Safety Takeaways From Recent Data on JAK Inhibitors for MF
    EP. 9: The FREEDOM-2 Trial: Efficacy and Safety of Fedratinib in Patients With MF Previously Treated With Ruxolitinib
    EP. 10: Selection and Sequencing of JAK Inhibitors for Patients With MF
    EP. 11: Individualizing Therapy Goals for Patients With Myelofibrosis
    EP. 12: Emerging Treatments for Myelofibrosis
    x